0001209191-22-028679.txt : 20220512
0001209191-22-028679.hdr.sgml : 20220512
20220512200113
ACCESSION NUMBER: 0001209191-22-028679
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220510
FILED AS OF DATE: 20220512
DATE AS OF CHANGE: 20220512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galindo Alejandro
CENTRAL INDEX KEY: 0001821447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50865
FILM NUMBER: 22919716
MAIL ADDRESS:
STREET 1: 30930 RUSSELL RANCH RD
STREET 2: STE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MANNKIND CORP
CENTRAL INDEX KEY: 0000899460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133607736
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
BUSINESS PHONE: 818-661-5000
MAIL ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-10
0
0000899460
MANNKIND CORP
MNKD
0001821447
Galindo Alejandro
1 CASPER STREET
DANBURY
CT
06810
0
1
0
0
EVP Endocrine Business Unit
Restricted Stock Unit
2022-05-10
4
A
0
90000
0.00
A
666690
D
Restricted Stock Unit
2022-05-10
4
A
0
110000
0.00
A
776690
D
Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date.
The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
/s/ Alejandro Galindo
2022-05-12